Leading Players in Healthcare Cyber Security Market

A new report from Transparency Market Research, titled ‘Healthcare Cyber Security Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2016 - 2023,’ states that the global market is expected to expand at a rapid pace during the period between 2016 and 2023 due to increasing cyber-attack threats, improvements in healthcare infrastructure, and increasing spending.

Cybersecurity technologies are fast evolving across the globe owing to the changing digital landscape, where security threats are becoming more damaging and smarter. Today, amid the connected health environment, cyber security is not an option, rather it is a compulsion. For every organization, cyber security has become a strategic asset. The healthcare industry is increasingly implementing healthcare IT infrastructure to easily access, send, receive, and manage health care data. The rise in the patent violation cases, medical identity frauds, loss of patient information, and business record breaches are predicted to propel the global healthcare cyber security market in the years to come.

The global healthcare cyber security market is segmented on the basis of end user, region, and solution type. By region, the global healthcare cyber security market is divided into North America, Europe, Asia Pacific, and Rest of the World. Currently, North America dominates the global healthcare cyber security market owing to the increasing presence of a developed medical and healthcare infrastructure. Going forward, factors such as the increasing spending on healthcare information technology, the availability of medical and pharmaceutical devices, and the rising government support are expected to propel the North America healthcare cyber security market.

Asia Pacific is expected to be the attractive market in the years to come owing to economic developments in nations such as India, Japan, and China. Further, the Asia Pacific healthcare cyber security market is expected to grow swiftly due to the rapid enhancements in the healthcare sector. Developing a technically advanced cyber-system platform is a necessity today. Leading players such as Cisco Systems, Inc., MacAfee, Inc., Symantec Corporation, IBM Corporation, Palo Alto Networks, Inc., Lockheed Martin Corporation, Northrop Grumma Corporation, FireEye, Inc., and Kaspersky Lab are taking efforts to introduce new healthcare cyber security platforms in the global market.

Request for Sample: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=11078

By solution type, the global healthcare cyber security market is classified into identity and access management, intrusion detection system, risk and compliance management, antivirus, data encryption software, antimalware, firewall, and others. Currently, the global healthcare cyber security market is dominated by the identity and access management segment. Based on end user, the global healthcare cyber security market is classified into medical devices companies, pharmaceutical and chemical manufacturers, hospitals, and health insurance companies.

Diagnostic Testing of STDs Market: Challenges and Opportunities

Transparency Market Research has published a new report on the global diagnostic testing of STDs market. According to the report, the global diagnostic testing of STDs market is expected to progress from US$65.9 bn in 2012 to US$108.5 bn by 2019. The report, titled ‘Diagnostic Testing of STDs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019,’ states that the global market is expected to expand at an 8.10% CAGR during the period between 2013 and 2019. Factors such as the rising prevalence of STDs, the implementation of national screening programs, and favorable reimbursement policies are expected to propel the global diagnostic testing of STDs market in the years to come.

Sexually transmitted diseases (STDs) spread primarily because of person-to-person sexual contact. There are many techniques used to diagnose sexually transmitted diseases. Undiagnosed STDs may have many critical implications on maternal, reproductive, and newborn health. For example, 10% to 15% of women suffering from untreated Chlamydia infection have the possibility of developing a symptomatic pelvic inflammatory disease. Untreated and undiagnosed sexually transmitted diseases such as syphilis could lead to congenital syphilis, which is associated with the high risk of pre-term birth. The prenatal spread of herpes simplex virus infection is associated with a high risk of various neurological problems and even death. Untreated and undiagnosed STDs increase the risk of acquisition and transmission of HIV. The timely diagnosis of STDs is imperative to prevent the transmission of STDs and reduce the risk of sexually transmitted infections.

Factors such as the presence of many STD-affected people in out-of-reach areas, stringent government regulations, and the stigma associated with voluntary STD testing are predicted to hamper the growth of the global diagnostic testing of STDs market in the coming few years. The increasing number of national screening programs across countries is likely to create opportunities for POC and laboratory test providers. The reduction in the number of visits to specialized GUM and STD clinics is creating many opportunities for private and public labs. All these factors are predicted to create growth opportunities in the global diagnostic testing of STDs market in the coming few years.

The global diagnostic testing of STDs market is segmented on the basis of region, location, and type. Based on type, the global diagnostic testing of STDs market is classified into herpes simplex virus (HSV) testing, chancroid testing, humap papilloma virus (HPV) testing, HIV testing, P&S syphilis testing, chlamydia testing, and gonorrhea testing. Every year, approximately 300,000 cervical cancer deaths are registered, occurring due to HPV. The HPV testing segment is expected to expand at a 70% CAGR during the period between 2013 and 2019. By location, the global diagnostic testing of STDs market is classified into lab testing and point-of-care testing.

Get a Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1631

Geographically, the global diagnostic testing of STDs market is divided into Asia Pacific, Europe, North America, and Rest of the World. Currently, North America dominates the global diagnostic testing of STDs market due to the growing prevalence of diseases such as gonorrhea, P&S syphilis, and chlamydia. In terms of testing volume, the Asia Pacific diagnostic testing of STDs market is expected to register steady growth in the years to come.

bioMerieux, Becton Dickinson & Company, Hologic. Inc., Danaher Corporation, and Roche Holding are some of the prominent companies operating in the global diagnostic testing of STDs market.

Active Pharmaceutical Ingredient Market - Latest Trends & Insights 2023

Active Pharmaceutical Ingredient (API) refers to a substance or substance combination used in manufacturing a drug product. The active pharmaceutical ingredient market has been categorized by manufacturing process, API type, drug type, therapeutic area and geography. Manufacturing processes in the global API market include captive and contract manufacturing. The captive API manufacturing segment comprises the active pharmaceutical ingredients produced for internal consumption of a pharmaceutical company. Captive manufacturing accounted for the highest market share in 2014, however the share of this market segment is expected to witness a decline due high degree of competition from contract manufacturing and reduced profitability and thus increased preference for outsourcing API production over captive production. Outsourcing production helps pharmaceutical companies focus on their core business of developing new drug products. Contract manufacturing is being preferred because of its advantage in terms of capital and labor costs, access to advanced manufacturing technologies, and benefits from the global distribution network.

The global active pharmaceutical market is segmented into API types: synthetic chemical API and biological API. The synthetic chemical API segment held the largest share of more than 70% of active pharmaceutical market in 2014. This market segment has evolved in the past few years due to innovations in the methods of synthesizing chemical APIs, which improves their stability and potency. The large volume of the demand is an important reason for the larger share of synthetic chemical API segment. On the other hand, the biological API market segment is expected to have the highest growth rate of 8.1% during the forecast period of 2015-2023. Large pharmaceutical companies are scaling down their small molecule manufacturing facilities to focus on biologic drugs, thereby presenting greater opportunities for contract manufacturing companies. The overall cost of drug development program for biologics is less as compared to chemical APIs, primarily because of high success rates in the pipeline phase. This factor has attracted higher investments in the biologics and biosimilars market.

Drug types in the global API market include branded prescription drug, generic prescription drug and OTC drugs. The branded API segment accounted for the largest share of 76% in the global API market in 2014. The factors driving the branded prescription drugs include government initiatives that has lowered the copayment on generics while raising it on the branded drugs. The increasing demand for biological drugs and supportive policies of the European Union toward biosimilars is also one of the major driving factors to boost branded API market. Moreover, the generic prescription drugs segment is expected to grow at the highest rate of 7.3% during the forecast period. With the rising cost of healthcare, governments and payers are pushing for the increasing generics consumption over branded drugs, thus driving growth of the generic APIs market. Over-the-counter (drugs) are considered sufficiently safe and effective for use without prescriptions from health care professionals and hence would continue to grow at a steady rate during the forecast period.

Based on the therapeutic area, the global API market is segmented into various disorders such as cardiovascular, metabolic, disorders, oncology, musculoskeletal, non-steroidal anti-inflammatory drugs (NSAIDs), and others. The cardiovascular disorder segment held the largest share of global active pharmaceutical ingredient market during the forecast period. Cardiovascular, metabolic, and neurological disorders held a combined market share of over 50% in 2014 due to the rising geriatric population, increasing prevalence of cardiovascular diseases, diabetes and neurological disease globally. Whereas, the oncology segment is expected to grow at the highest rate of 8.2% during the forecast period owing to the rising prevalence of cancer. The significant growth observed in oncology API has helped companies to prefer specialized manufacturing plants for oncology drugs. The musculoskeletal disorders, NSAIDs and other therapeutics area is anticipated to grow at a steady rate during the forecast period of 2015 to 2023.

Download Brochure: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1690

Geographically, North America dominated the active pharmaceutical ingredient market in 2014 with a share of 35.1% owing to factors such as higher consumption of API due to the presence of major pharmaceutical companies in this region. Biologics have become one of the top-selling drugs in North America. Thus, the expected market entry of biosimilars with flexible regulatory process would further boost the API market in North America. Japan, China, India and South Korea, the leading pharmaceutical hubs in Asia are majorly responsible for almost 30% of the total market share placing the region at the second position in the world. Major factors driving the API markets in China and India are the availability of low cost production facilities and labor cost. Other factors driving the market in the region include the tax incentives, rising government expenditure on health care and government plans to restructure the fragmented industry. Europe accounted for a market share of 21.6% in 2014. The governments of various countries in Europe have started supporting the manufacture of generic drugs post the financial crisis. Patent expirations of major blockbuster drugs in Europe would fuel the growth of the API market in the near future. Demand for generic drugs is increasing not only in developed countries, but also in developing and underdeveloped countries in South America and Africa. Brazil and South Africa are the important centers of pharmaceutical manufacturing in this regional segment. Factors boosting the growth of the market in developing regions are cost-efficient manufacturing, large number of patients, rising demand for generic drugs, and improvement in the healthcare infrastructure.

Teva Pharmaceutical Industries Ltd dominated active pharmaceutical ingredients market in 2014. Major factors attributed to its dominance are broad product portfolio and high market penetration. Zhejiang Medicine Co., Ltd. and Zhejiang NHU Co., Ltd secured the second market position in 2015. North China Pharmaceutical Group Corp. (NCPC) and Northeast Pharmaceutical Group Co., Ltd. held the third position in 2015. Other players in the active pharmaceutical ingredients market include Dr.Reddy's Laboratories Limited, Sandoz (Novartis AG), Aurobindo Pharma Limited, Zhejiang Hisun Pharmaceutical Co., Ltd. and Zhejiang Huahai Pharmaceuticals Co., Ltd. and others.

Peptide Therapeutics Market - Recommendations for 2016; Emerging Trends and New Technologies Research 2014 - 2020

Therapeutic peptides are defined as short amino acid chains that have potential in managing disease symptoms, and in some cases cure them. The industry defines peptides as molecules shorter than 100 amino acids; while longer amino acid chains can be monoclonal antibodies and proteins. Insulin was the first peptide to be isolated and administered therapeutically, and is still the most commonly prescribed peptide, having been used for over half a century. Peptides have been explored for the treatment of various conditions such as cancer, cardiovascular disorders, respiratory disorders, blood disorders, central nervous system disorders and various others.

The peptide therapeutics market has developed at a significant pace in the recent past, leading to unparalleled growth in the number of regulatory approvals received in 2012. Thus, the increase in number of approved peptide-based drug products and expanding range of medical indications projects the increasing maturity of peptides as a class of pharmaceutical actives. Therapeutic peptides are approved for various application areas such as cancer, cardiovascular, central nervous system, gastrointestinal, infection, metabolic, pain, and respiratory. Cancer was estimated to be the largest application segment of the peptide therapeutics market in 2013; while the respiratory segment is expected to grow at the highest CAGR, due to the recent approval of Surfaxin (lucinactant). Major drugs driving growth of the overall peptide therapeutics market include Angiomax, Copaxone, Forteo, Sandostatin, Velcade, Victoza and Zoladex. As these drugs lose their patent exclusivity in the near future, the market for generic peptide drugs would flourish. However, difficulty in synthesis of complex peptides has restricted growth of the generic peptide drugs market.

Patent expiry has been the prime factor impeding market growth; while at the same time has also allowed deeper market penetration in low and middle income countries. The market is also restrained due to unavailability of convenient routes of drug administration, and lower drug stability at room temperature. Scientists, however, are trying to overcome these drawbacks through consistent research and development. With an escalating number of peptide therapeutic drug approvals and consistent launch of generics, the demand for peptide APIs is expected to rise in the near future. Hence, API manufacturers are trying to optimize economies of scale to reduce costs and also meet the rising peptide API demand. Thus, the supply side of the peptide therapeutics value chain would decide the fate of the global market.

Get a Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=418

The global peptide therapeutics market is largely concentrated in the western countries of North America and Europe, which account for more than 60% of the market share. Although these regions are currently the largest market segments, the compounded annual growth rate of the market in these regions is expected to be slower as compared to Asia Pacific. India, China and Japan are major countries driving the peptide therapeutics market in the Asia Pacific region. Japan is the second-largest individual pharmaceutical market, while India and China have large patient population due to high disease prevalence. Rapidly developing economy and increasing awareness about various disease treatments are other factors driving the market. India and China have emerged as major peptide API suppliers globally.

Key players in the market include Amgen, Inc., AstraZeneca plc, Eli Lilly & Co., Ipsen S.A., Merck & Co., Novartis AG, Novo Nordisk A/S, Roche Holdings AG, Sanofi, Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Limited. Leading API manufacturers include Bachem Holding AG, PolyPeptide Group. Peptisyntha Inc and Lonza Inc.

Internet of Things (IoT) in Healthcare Market size and Key Trends in terms of volume and value 2016-2024

Global Internet of Things (IoT) in Healthcare Market: Overview

The proliferation of the Internet of Things (IoT) in the healthcare market, which comprises systems and software, medical devices, and services, has had a significant impact on the overall healthcare sector and been immensely beneficial in remote clinical monitoring, chronic disease management, preventive care, assisted living, and personal fitness monitoring. Termed as a true game-changer for the healthcare industry, the Internet of Things has transformed the sector by lowering costs, improving efficiency, and bringing the focus back to quality patient care.

The IoT in healthcare market includes a number of implanted, wearable, and stationary medical devices used in clinical research organizations, research and diagnostic laboratories, hospitals, clinics, and surgical centers, and defense and government institutions. In the healthcare industry, the Internet of Things can be put to several applications, including clinical operations and workflow management, inpatient monitoring, telemedicine, connected imaging, and medication management. Bluetooth low energy (BLE), ZigBee, satellite, Wi-Fi, near-field communication (NFC), and cellular are some of the key connectivity technologies involved in IoT in healthcare.

The data in the report on the worldwide market for IoT in healthcare has been collated from several primary and secondary research sources, along with sharp insights and strategic recommendations from industry experts. The report is designed to help clients formulate profitable and actionable strategies to expand their businesses.

Global Internet of Things (IoT) in Healthcare Market: Key Trends and Opportunities

Considering that the global healthcare industry has been undergoing several changes in a bid to provide accessible, affordable, and quality patient care, advanced and cutting edge technologies are being developed to help the industry cope with these changes. The introduction of IoT in the healthcare sector has transformed the way health services are being delivered.

There are a number of factors driving the global market for IoT in healthcare. These include increasing global geriatric population, rising prevalence of various chronic diseases, the surging awareness levels pertaining to the availability of advanced disease management systems, the mounting demand for long-term and short-term healthcare services, and an overall improvement in data management, patient monitoring, and healthcare outcomes. The growing use of smartphones and the improved internet connectivity across the globe are also responsible for the expansion of the IoT in healthcare market.

Global Internet of Things (IoT) in Healthcare Market: Regional Outlook

The global market for IoT in healthcare is geographically segmented into North America, Europe, Asia Pacific, and Rest of the World. North America continues to be the highest revenue generating region and analysts predict that the region is likely to retain its lead in the global IoT in healthcare market throughout the forecast period. The rapid growth of the North America IoT in healthcare market can be attributed to the presence of advanced and sophisticated healthcare infrastructure, major technological advancements in the field of healthcare software and medical devices, increased levels of R&D initiatives in IoT, and high levels of disposable income.

The Asia Pacific market for IoT in healthcare has been identified as the most lucrative region and this geographical segment is projected to witness strong growth in the coming years. Rapid economic growth is one of the primary reasons for the future expansion of the IoT in healthcare in Asia Pacific, especially in countries such as China and India. Other factors impacting this regional market include improvement in healthcare infrastructure, rising disposable income levels, growing presence of IT-enabled healthcare services, increasing affordability of smartphones and various wearable medical devices, and changes in lifestyle habits.

Download Brochure: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=11975

Global Internet of Things (IoT) in Healthcare Market: Vendor Assessment

Adheretech, Cerner Corporation, PhysIQ, Stanley Healthcare, Qualcomm Life Inc., Cisco Systems, Medtronic Inc., GE Healthcare, Proteus Digital Health Inc., Microsoft Corporation, Diabetizer Ltd. & Co. KG, Philips, SAP SE, IBM Corporation, and Honeywell Care Solutions are some of the top companies competing in the global IoT in healthcare market. The nature of this market is immensely oligopolistic, wherein a handful of large, established players dominate the scene with strategies such as collaborative research and development, development of specialized products for specific applications, and acquiring startups with immense potential. This in turn, makes it difficult for smaller players and new entrants to venture into the IoT in healthcare market.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

Growing Prevalence of Chronic Diseases Drives Patient Engagement Solutions Market

Transparency Market Research has published a new report on the global patient engagement solutions market. As per the report, the global patient engagement solutions market is expected to expand at a 23.0% CAGR from 2015 to 2023. The report, titled ‘Patient Engagement Solutions Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023,’ states that the market will progress from US$6.66 bn in 2014 to US$34.94 bn by 2023. The introduction of IT in healthcare services and improvements in the quality of healthcare services are some of the factors expected to propel the global patient engagement solutions market in the near future.

Patient engagement solutions offer enhanced healthcare to patients by including electronic devices and advanced IT services in their medical routine. These medical services and solutions assist patients in taking better healthcare-related decisions, thus enabling a healthier life. To deliver enhanced quality healthcare services, patient engagement solutions are supported by healthcare organizations and hospitals. The basic need to use patient engagement solutions is to build a healthy relation between patients and healthcare service providers and promote active participation for self-care.

Since the inclusion of IT in the healthcare industry, the global patient engagement solutions market has gone through many developments. For example, the increasing adoption of electronic healthcare records systems is being seen because of the effective use of IT in healthcare services. Going forward, improved infrastructure is expected to propel the global patient engagement solutions market.

Patient engagement solutions offer many services such as lab reports, medication/appointment reminders, and healthcare tips. With enhanced patient engagement solutions, patients can manage their healthcare expenses in a better way. The global patient engagement solutions market is segmented on the basis of end user, region, and delivery mode. By delivery mode, the global patient engagement solutions market is classified into software as a service (SaaS), application managed services, and self-hosted services. In 2014, the global patient engagement solutions market was dominated by the self-hosted service segment. However, the SaaS segment is predicted to expand at a 23.60% CAGR from 2015 to 2023 owing to the increasing adoption of HCIT services by healthcare service providers and hospitals.

Download Brochure: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=4506

By end user, in 2014, the global market for patient engagement solutions was dominated by the hospitals and providers segment. Pharmaceutical companies and healthcare payers are two of the other end-user segments of patient management solutions. In 2014, the hospitals and providers segment accounted for 42.4% of the global patient engagement solutions market. However, the pharmaceutical companies segment is predicted to expand at a 24.1% CAGR from 2015 to 2023.

The global patient engagement solutions market is geographically spread across regions such as North America, Latin America, Asia Pacific, the Middle East and Africa, and Europe. Some of the key companies operating in the global patient engagement solutions market are McKesson Corporation, Medecision, Inc., Emmi Solutions, LLC, GetWellNetwork Inc., Athena Health, Inc., Axial Exchange Inc., Phytel, Inc. (An IBM Company), Allscripts Healthcare Solutions, and Orion Health Ltd.

Breast Cancer Therapeutics Pipeline Analysis Market Trends & Forecast up to 2023

The report on breast cancer therapeutics: pipeline analysis market studies the future market of breast cancer drugs on the basis of the molecules which are currently under pipeline. Breast cancer usually originates from the inner lining of milk ducts or lobules responsible for supplying the milk. This is a malignant type of tumor that can spread to other cells present in the body. The type of cancer which starts in lobules is referred as lobular carcinoma, while the other that develops from milk ducts is called ductal carcinoma. Breast cancer is the most common type of invasive cancer affecting women worldwide. The drugs that are under clinical trial phase III have been considered to estimate the market for the forecast period from 2015 to 2023. Stakeholders for this report include the companies engaged in research and development of breast cancer drugs, and sponsoring of clinical trials studies and new entrants that are planning to invest in the breast cancer pipeline drugs.

Browse Full Report with TOC: http://www.transparencymarketresearch.com/breast-cancer-therapeutics-pipeline-analysis-market.html

The executive summary section of the breast cancer therapeutics: pipeline analysis market report summarizes the market analysis of the major pipeline drugs in the breast cancer market. It also provides information about the key pipeline molecules available in phase I and phase II clinical trials along with a list of major market players who are sponsoring these studies.

The market overview section of the report provides a detailed qualitative information about breast cancer. Factors such as epidemiology of breast cancer across different geographical regions, types of breast cancer, and other possible treatments for breast cancer are explained along with relevant statistics in this section. A list of companion diagnostic devices with respect to the major target drugs used for the treatment of breast cancer is also included in the report to provide a brief idea about the current scenario of the breast cancer market. Major business strategies applied in the market by the major players to strengthen their breast cancer pipeline have also been explained with the help of relevant examples. All these factors have been provided to help new entrants and market players understand the important aspects of the breast cancer market in the current scenario and decide upon strategic decisions that would assist them in generating a strong pipeline for breast cancer therapeutic drugs.

Get Free Sample @ http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=5678

Based on clinical phases, the breast cancer therapeutics: pipeline analysis market has been segmented into three major categories: phase I drug candidates, phase II drug candidates, and phase III drug candidates. Tabular representation for phase I drug candidates and phase II drug candidates has been provided, which summarizes information about promising drug candidates under clinical trials and associated conditions, sponsors and collaborators, primary outcome measure, time frame, and status about designated safety issue. The phase III drug candidates section is further differentiated into various key molecules that are expected to give promising results. These molecules include Palbociclib (PD-0332991) + Fulvestrant, NK105, BKM120, NKTR-102, Neratinib, Olaparib, DOXIL, ABP 980, CT-P6, and Trastuzumab Emtansine + Pertuzumab. Commercial analysis for all these molecules is provided by forecasting the anticipated market revenue from the expected year of commercialization until 2023. Compound annual growth rate (CAGR %) for each of these molecules is also provided for the period from the expected commercialization year to 2023.

A list of recommendations has been provided for new entrants as well as existing market players to assist in taking strategic initiatives in a bid to establish a strong pipeline for breast cancer therapeutic drugs. The report also profiles major players in the breast cancer therapeutics: pipeline analysis market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Major players profiled in this report include AstraZeneca plc, Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Novartis International AG, Pfizer, Inc., and Sanofi.

Read Full Press Release @ http://www.transparencymarketresearch.com/pressrelease/breast-cancer-therapeutics-pipeline-analysis-market.htm